Cemsidomide Shows 53% ORR, CRs in Phase 1 Multiple Myeloma Data, Positioning as Potential Best-in-Class Degrader
CCCC has more than doubled off its 52-week low of $1.36.
Summary
C4 Therapeutics presented compelling Phase 1 data for cemsidomide in heavily pretreated relapsed/refractory multiple myeloma at the EHA 2026 Congress. The drug demonstrated a 53% overall response rate (ORR) at the recommended Phase 2 dose, including complete responses and minimal residual disease (MRD) negativity, with a median duration of response of 7.9 months. This positive efficacy, coupled with a favorable tolerability profile, positions cemsidomide as a potential best-in-class IKZF1/3 degrader. This clinical update significantly de-risks the program and is a crucial step for the company's pipeline, following its Q1 earnings report in May which confirmed a cash runway through 2028.
At the time of this announcement, CCCC was trading at $3.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $427.9M. The 52-week trading range was $1.36 to $4.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.